The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion
Open accessAbstract
OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorption. RESEARCH DESIGN AND METHODS: This two-period, crossover study evaluated effects of canagliflozin on intestinal glucose absorption in 20 healthy subjects using a dual-tracer method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal mixed-meal tolerance test. Plasma glucose, 3H-glucose, 14C-glucose, and insulin were measured frequently for 6 h to calculate rates of appearance of oral glucose (RaO) in plasma, endogenous glucose production, and glucose disposal. RESULTS: Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0–2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0–6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC RaO by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002). Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003). A modest (∼10%) reduction in acetaminophen absorption was observed over the first 2 h, but this difference was not sufficient to explain the reduction in RaO. Total glucose disposal over 0 to 6 h was similar across groups. CONCLUSIONS: Canagliflozin reduces postprandial plasma glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and delaying RaO, likely due to intestinal SGLT1 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Gorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Rates of EGP and Rd Before the MMTT, the rate of EGPwas;2 mg/kg/min in both treatment groups, consistent with values reported in other studies in healthy subjects (23,24).”
ResultOvbiagele, B. I., Kidwell, C. S., & Saver, J. L. (2005) · Cited by 454
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
The Disposal of an Oral Glucose Load in Healthy Subjects: A Quantitative Study
Ferrannini, E., Bjorkman, O., Reichard, G. A., Pilo, A., Olsson, M., Wahren, J., & DeFronzo, R. A. (1985) · Diabetes · doi:10.2337/diab.34.6.580 · Cited by 439
Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., Capuano, G., Canovatchel, W., & for the Canagliflozin DIA 2001 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1926 · Cited by 421
Self-citationNomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100332n · Cited by 385
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373 · cited 1×
“The early increments in GLP-1 and PYY (occurring before ingested nutrients have reached the more distal intestine) have been commonly reported in other studies (25), and the source of this early GLP-1 and PYY secretion remains uncertain, with possibilities including 1) a neural signal from the proximal small intestine…”
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Stenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Vallon, V. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-110046 · Cited by 348
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 332
Bilezikian, J. P., Watts, N. B., Usiskin, K., Polidori, D., Fung, A., Sullivan, D., & Rosenthal, N. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1860 · Cited by 273
Self-citationCarbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
Self-citationPessoa, T. D., Campos, L. C. G., Carraro-Lacroix, L., Girardi, A. C. C., & Malnic, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060588 · Cited by 184
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0457-8 · Cited by 140
Intestinal SGLT1 in metabolic health and disease
Lehmann, A., & Hornby, P. J. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00068.2016 · Cited by 104
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“[21] In a cross-over study in healthy volunteers, canagliflozin 300 mg provided significantly smaller postprandial glucose excursions than dapagliflozin 10 mg.”
BackgroundLin, X.-F., Cui, X.-N., Yang, J., Jiang, Y.-F., Wei, T.-J., Xia, L., Liao, X.-Y., Li, F., Wang, D.-D., Li, J., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01389-3 · Cited by 69
Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
(2015) · Europe PMC (PubMed Central) · Cited by 18
Bloomgarden, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12065 · Cited by 13
Metadata
- Authors
- Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T. P., Ghosh, A., Vaccaro, N., Farrell, K., Rothenberg, P., & Henry, R. R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-11
- Volume
- 36
- Issue
- 8
- Pages
- 2154-2161
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2131135469
- Cited by
- 261
- References
- 28
- FWCI
- 27.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.